by United Pompe | Jul 26, 2018 | News
Higher Lumizyme Dose May Help Prevent Pompe Progression in Infants, Case Report Suggests JULY 18, 2018BY ALICE MELAOIN NEWS. Treatment with Lumizyme(alglucosidase alfa) at double the approved dose may help prevent the rapid decline of respiratory...
by United Pompe | Jul 10, 2018 | News
Amicus Therapeutics Strengthens Biologics Business Strategy
by United Pompe | Mar 4, 2017 | News
PR NewsWire March 3, 2017 Valerion Therapeutics Demonstrates a New Mechanism for Treating Pompe Disease Concord, MA– March 3, 2017– Valerion Therapeutics announced today that it has developed a fusion protein, VAL-1221, which combines its proprietary...
by United Pompe | Dec 8, 2016 | News
December 8, 2016 Amicus Therapeutics Announces Positive Preliminary Data from Phase 1/2 Study of Novel Treatment Paradigm for Pompe Disease ATB200/AT2221 Safety Data Show No Infusion-Associated Reactions Following 100+ Infusions Clinical Pharmacokinetic (PK) Profile...
by United Pompe | Nov 15, 2016 | News
PRESS RELEASE Sanofi Genzyme Begins Pivotal Phase 3 Trial of NeoGAA Investigational Second-Generation Therapy for Pompe Disease Cambridge, Mass. – November 4, 2016 – Sanofi Genzyme, the specialty care global business unit of Sanofi, announced today that the...
